Figure S2 from Loss of LGR5 through therapy-induced downregulation or gene ablation is associated with resistance and enhanced MET-STAT3 signaling in colorectal cancer cells

shows inhibitors of IL6/Gp130 and EGFR do not attenuate STAT3 activation in LGR5 KD/KO CRC cells, LGR5 KD in DLD-1 cells increases MET-STAT3 activation, and the effects of MET and STAT3 inhibitors at different time-points